HansBiomed Corporation (KOSDAQ:042520)

South Korea · Delayed Price · Currency is KRW

20,350

-2,550 (-11.14%)

At close: Jul 20, 2026

127.37% (1Y)

Market Cap	290.22B +149.7%
Revenue (ttm)	110.50B +31.0%
Net Income	-24.85B
EPS	-1,854.43
Shares Out	14.26M
PE Ratio	n/a
Forward PE	13.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150,497
Open	22,500
Previous Close	22,900
Day's Range	20,100 - 22,500
52-Week Range	6,970 - 57,800
Beta	1.89
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1990

Employees 299

Stock Exchange KOSDAQ

Ticker Symbol 042520

Full Company Profile

Financial Performance

In fiscal year 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.

Financial Statements